Purespring Therapeutics has raised £80 million in an oversubscribed Series B financing
LONDON: Syncona Ltd’s portfolio company Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases has raised £80 million in...
Climate tech company, GALY, raises $33 million in Series B financing
LONDON: Agronomics’ portfolio company GALY CO. has closed an oversubscribed US$ 33 million Series B financing led by Breakthrough Energy Ventures LLC, with additional participation from...
Beacon Therapeutics raises $170 million in a Series B financing
Syncona Ltd announced that it has committed $42.5 million (£33.5 million) to a $170 million (£134 million) Series B financing of its portfolio company Beacon...
Syncona co-leads Series B financing in Quell Therapeutics of up to $156 million
LONDON, UK: Syncona Ltd has committed $25 million (£19 million) to Quell Therapeutics, a world leader in developing engineered T-regulatory (Treg) cell therapies for serious...
CinCor Pharma raises $143 million in Series B Financing
LONDON, UK: RTW Venture Fund Limited notes the announcement by CinCor Pharma Inc. on 12 October 2021 of its completion of a US$143 million Series...